IPC_6261(寄生原生动物），NR-1_Vaccinia virus

MRA-1284??Plasmodium falciparum, IPC_6261(Parasitic Protozoa)|Plasmodium falciparum|IPC_6261|-80°C or colder|D MénardAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Plasmodium falciparum, Strain IPC_6261, MRA-1284, contributed by Didier Ménard."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. Plasmodium falciparum (P. falciparum), strain IPC_6261 was isolated in 2012 from the blood of a human patient with malaria in Cambodia. P. falciparum, strain IPC_6261 was deposited as a piperaquine-resistant strain obtained from culture-adapted parasites harboring the C580Y K13 mutation conferring artemisinin-resistance. The in vitro susceptibility profile of P. falciparum, strain IPC_6261 is as follows: chloroquine IC₅₀ = 166 nM, dihydroartimisinin IC₅₀ = 0.81 nM, mefloquine IC₅₀ = 21.7 nM and piperaquine IC₅₀ = non-interpretable. P. falciparum, strain IPC_6261 gave a ring-stage survival assay (RSA_0-3h) rate of 20.4% when exposed to dihydroartemisinin, and gave a piperaquine survival assay (PSA) rate of 70.6%. Each vial contains approximately 0.5 mL of P. falciparum- infected human blood in Glycerolyte 57 solution (1:5).